Remove Chemotherapy Remove Events Remove Generic Medicine
article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.